Pioglitazone and Bladder Cancer
Open accessAbstract
OBJECTIVE: The association between pioglitazone and bladder cancer has not been investigated in Asians. We aimed to investigate this association. RESEARCH DESIGN AND METHODS: A total of 1,000,000 individuals were randomly sampled from the National Health Insurance database, and incident cases of bladder cancer during the period from 1 January 2006 to 31 December 2009 were analyzed among 54,928 patients with type 2 diabetes and without previous bladder cancer. RESULTS: Among 165 incident case subjects, 10 (0.39%) were ever users and 155 (0.30%) were never users of pioglitazone (adjusted hazard ratio in full model 1.305 [95% CI 0.661–2.576]). All bladder cancer in ever users occurred within a duration of therapy <24 months, suggesting an early effect of pioglitazone on bladder cancer or late use of pioglitazone in high-risk patients. CONCLUSIONS: The association between pioglitazone and bladder cancer was not significant. However, confirmation of this finding is required because of the possible lack of statistical power owing to the small number of events.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There is some suggestion of a possible link between pioglitazone and bladder cancer, so individuals with a history of bladder cancer or unexplained hematuria should probably not receive this drug.
“There is also some suggestion of a possible link between pioglitazone and bladder cancer and therefore individuals with a history of bladder cancer or unexplained hematuria should probably not receive this drug.98,99”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · see citing works
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · see citing works
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · see citing works
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918 · see citing works
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625 · see citing works
SIMPLE METHOD TO CALCULATE THE CONFIDENCE INTERVAL OF A STANDARDIZED MORTALITY RATIO (SMR)
Ulm, K. (1990) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115507 · Cited by 552 · see citing works
Estrategias para la elaboración de modelos estadísticos de regresión
Núñez, E., Steyerberg, E. W., & Núñez, J. E. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.01.019 · Cited by 275 · see citing works
Piccinni, C., Motola, D., Marchesini, G., & Poluzzi, E. (2011) · Diabetes Care · doi:10.2337/dc10-2412 · Cited by 239 · see citing works
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes
Dormandy, J., Bhattacharya, M., & van Troostenburg, A. (2009) · Drug Safety · doi:10.2165/00002018-200932030-00002 · Cited by 227 · see citing works
Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan
Tseng, C. (2011) · Diabetologia · doi:10.1007/s00125-011-2171-z · Cited by 139 · see citing works
Self-citationDiabetes and Risk of Prostate Cancer
Tseng, C. (2011) · Diabetes Care · doi:10.2337/dc10-1640 · Cited by 123 · see citing works
Self-citationTseng, C., Chong, C., Tseng, C., & Chan, T.-T. (2009) · Annals of Medicine · doi:10.1080/07853890902729778 · Cited by 51 · see citing works
Self-citationTseng, C. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr334 · Cited by 42 · see citing works
Self-citationYang, X., & Chan, J. C. N. (2011) · Diabetes Care · doi:10.2337/dc11-0627 · Cited by 12 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958 · see citing works
Azoulay, L., Yin, H., Filion, K. B., Assayag, J., Majdan, A. A., Pollak, M., & Suissa, S. (2012) · BMJ · doi:10.1136/bmj.e3645 · Cited by 267 · see citing works
Pioglitazone use and risk of bladder cancer: Population based cohort study
Tuccori, M., Filion, K. B., Yin, H., Yu, O. H., Platt, R. W., & Azoulay, L. (2016) · BMJ · doi:10.1136/bmj.i1541 · Cited by 237 · see citing works
Insulin Resistance and Cancer: In Search for a Causal Link
CHIEFARI, E. D., Mirabelli, M., Vignera, S. L., Tanyolaç, S., FOTI, D. P., Aversa, A., & Brunetti, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011137 · Cited by 175 · see citing works
The Influence of Type 2 Diabetes and Glucose-Lowering Therapies on Cancer Risk in the Taiwanese
Hsieh, M.-C., Lee, T.-C., Cheng, S.-M., Tu, S., Yen, M., & Tseng, C. (2012) · Experimental Diabetes Research · doi:10.1155/2012/413782 · Cited by 163 · see citing works
Self-citationPioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis
on behalf of the Scottish Diabetes Research Network Epidemiology Group and the Diabetes and Cancer Research Consortium, Levin, D., Bell, S., Sund, R., Hartikainen, S. A., Tuomilehto, J., Pukkala, E., Keskimäki, I., Badrick, E., Renehan, A. G., et al. (2015) · Diabetologia · doi:10.1007/s00125-014-3456-9 · Cited by 158 · see citing works
Pioglitazone and bladder cancer risk: a systematic review and meta‐analysis
Tang, H., Shi, W., Fu, S., Wang, T., Zhai, S., Song, Y., & Han, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1354 · Cited by 157 · see citing works
Colmers-Gray, I. N., Bowker, S. L., Majumdar, S. R., & Johnson, J. A. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.112102 · Cited by 156 · see citing works
Pioglitazone and risk of bladder cancer: a meta‐analysis of controlled studies
Ferwana, M. S., Firwana, B., Hasan, R., Al-Mallah, M. H., Kim, S., Montori, V. M., & Murad, M. H. (2013) · Diabetic Medicine · doi:10.1111/dme.12144 · Cited by 147 · see citing works
Cancer Risk for Patients Using Thiazolidinediones for Type 2 Diabetes: A Meta-Analysis
Bosetti, C., Rosato, V., Buniato, D., Zambon, A., Vecchia, C. L., & Corrao, G. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0302 · Cited by 144 · see citing works
The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
Yau, H., Rivera, K., Lomonaco, R., & Cusi, K. J. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0378-8 · Cited by 139 · see citing works
SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives
Dutka, M., Bobiński, R., Francuz, T., Garczorz, W., Zimmer, K., Ilczak, T. P., Ćwiertnia, M., & Hajduga, M. B. (2022) · Cancers · doi:10.3390/cancers14235811 · Cited by 134 · see citing works
Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta‐analysis
Turner, R. M., Kwok, C. S., Chen‐Turner, C., Maduakor, C. A., Singh, S., & Loke, Y. K. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12306 · Cited by 126 · see citing works
Mamtani, R., Haynes, K., Bilker, W. B., Vaughn, D. J., Strom, B. L., Glanz, K., & Lewis, J. D. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs328 · Cited by 119 · see citing works
Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials
Monami, M., Dicembrini, I., & Mannucci, E. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0504-8 · Cited by 115 · see citing works
Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
Davidson, M., Mattison, D. R., Azoulay, L., & Krewski, D. R. (2017) · Critical Reviews in Toxicology · doi:10.1080/10408444.2017.1351420 · Cited by 114 · see citing works
Diabetes and gastric cancer: The potential links
Tseng, C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1701 · Cited by 106 · see citing works
Self-citationA Review on the Relationship between SGLT2 Inhibitors and Cancer
Lin, H.-W., & Tseng, C. (2014) · International Journal of Endocrinology · doi:10.1155/2014/719578 · Cited by 99 · see citing works
Self-citationTseng, C. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.08.007 · Cited by 94 · see citing works
Self-citationLatest insights into the risk of cancer in diabetes
Noto, H., Goto, A., Tsujimoto, T., Osame, K., & Noda, M. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12068 · Cited by 88 · see citing works
Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
Filipova, E. P., Uzunova, K. H., Kalinov, K., & Vekov, T. Y. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0273-4 · Cited by 88 · see citing works
Kasuga, M., Ueki, K., Tajima, N., Noda, M., Ohashi, K., Noto, H., Goto, A., Ogawa, W., Sakai, R., Tsugane, S., et al. (2013) · Cancer Science · doi:10.1111/cas.12203 · Cited by 82 · see citing works
Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus
Tseng, C. (2016) · Aging · doi:10.18632/aging.101019 · Cited by 82 · see citing works
Self-citationErdmann, E., Harding, S., Lam, H., & Perez, A. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12608 · Cited by 80 · see citing works
Xu, Y., Wu, Y., & Huang, Q. (2017) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-017-4480-z · Cited by 79 · see citing works
Metformin Reduces Thyroid Cancer Risk in Taiwanese Patients with Type 2 Diabetes
Tseng, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109852 · Cited by 78 · see citing works
Self-citationBailey, T. S. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.06.009 · Cited by 76 · see citing works
Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan
Tseng, C. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.03.059 · Cited by 71 · see citing works
Self-citationThe current role of thiazolidinediones in diabetes management
Rizos, C. V., Kei, A. A., & Elisaf, M. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1737-4 · Cited by 70 · see citing works
Singh, S., & Bhansali, A. K. (2016) · BMC Dermatology · doi:10.1186/s12895-016-0049-y · Cited by 71 · see citing works
Hsiao, F., Hsieh, P.-H., Huang, W.-F., Tsai, Y., & Gau, C. (2013) · Drug Safety · doi:10.1007/s40264-013-0080-4 · Cited by 69 · see citing works
Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus
Tseng, C. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2649 · Cited by 67 · see citing works
Self-citationUse of metformin and risk of kidney cancer in patients with type 2 diabetes
Tseng, C. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.027 · Cited by 66 · see citing works
Self-citationObservational follow‐up of the PROactive study: a 6‐year update
Erdmann, E., Song, E., Spanheimer, R. G., de Bruyn, A.-R. V. T., & Pérez, A. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12180 · Cited by 65 · see citing works
A Review on the Association between Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer
Chiu, W.-Y., Shih, S.-R., & Tseng, C.-H. (2012) · Experimental Diabetes Research · doi:10.1155/2012/924168 · Cited by 63 · see citing works
Self-citationZhu, Z., Shen, Z., Lu, Y., Zhong, S., & Chen, X. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.05.006 · Cited by 62 · see citing works
Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes
Tseng, C. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0562-6 · Cited by 55 · see citing works
Self-citationMetformin may reduce oral cancer risk in patients with type 2 diabetes
Tseng, C. (2015) · Oncotarget · doi:10.18632/oncotarget.6626 · Cited by 52 · see citing works
Self-citationAn Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49 · see citing works
Self-citationPeroxisome Proliferator-Activated Receptor Agonists and Bladder Cancer: Lessons from Animal Studies
Tseng, C., & Tseng, F.-H. (2012) · Journal of Environmental Science and Health Part C · doi:10.1080/10590501.2012.735519 · Cited by 49 · see citing works
Self-citationTseng, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142480 · Cited by 47 · see citing works
Self-citationHe, S., Tang, Y.-H., Zhao, G., Yang, X., Wang, D., & Zhang, Y. (2013) · Tumor Biology · doi:10.1007/s13277-013-1278-x · Cited by 44 · see citing works
Metformin use and cervical cancer risk in female patients with type 2 diabetes
Tseng, C. (2016) · Oncotarget · doi:10.18632/oncotarget.10934 · Cited by 44 · see citing works
Self-citationTseng, C. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-7 · Cited by 42 · see citing works
Self-citationLin, H. C., Hsu, Y.-T., Kachingwe, B., Hsu, C.-Y., Uang, Y., & Wang, L.-H. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12151 · Cited by 40 · see citing works
A Review on Thiazolidinediones and Bladder Cancer in Human Studies
Tseng, C. (2014) · Journal of Environmental Science and Health Part C · doi:10.1080/10590501.2014.877645 · Cited by 41 · see citing works
Self-citationSitagliptin and pancreatic cancer risk in patients with type 2 diabetes
Tseng, C. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12570 · Cited by 39 · see citing works
Self-citationPioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit
Ryder, R. E. J. (2014) · Diabetic Medicine · doi:10.1111/dme.12627 · Cited by 37 · see citing works
Report of the JDS/JCA Joint Committee on Diabetes and Cancer
Kasuga, M., Ueki, K., Tajima, N., Noda, M., Ohashi, K., Noto, H., Goto, A., Ogawa, W., Sakai, R., Tsugane, S., et al. (2013) · Diabetology International · doi:10.1007/s13340-013-0121-3 · Cited by 37 · see citing works
Carta, A. R., & Simuni, T. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.963195 · Cited by 36 · see citing works
Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus
Tseng, C. (2016) · Oncotarget · doi:10.18632/oncotarget.13824 · Cited by 36 · see citing works
Self-citationYan, H., Xie, H., Ying, Y., Li, J., Wang, X., Xu, X., & Zheng, X. (2018) · Cancer Management and Research · doi:10.2147/cmar.s164840 · Cited by 36 · see citing works
The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone
Song, S. O., Kim, K. J., Lee, B., Kang, E. S., Soo, B., & Lee, H. C. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.5.371 · Cited by 35 · see citing works
Yang, D.-R., Lin, S.-J., Ding, X.-F., Miyamoto, H., Messing, E. M., Li, L.-Q., Wang, N., & Chang, C. (2013) · Urology · doi:10.1016/j.urology.2012.12.027 · Cited by 35 · see citing works
Jin, S., Song, S. O., Jung, C. H., Chang, J.-S., Suh, S., Kang, S. M., Jung, I., Park, C., Kim, J. H., Cho, J., et al. (2014) · Journal of Korean Medical Science · doi:10.3346/jkms.2014.29.2.238 · Cited by 34 · see citing works
Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes
Fujimoto, K., Hamamoto, Y., Honjo, S., Kawasaki, Y., Mori, K., Tatsuoka, H., Matsuoka, A., Wada, Y., Ikeda, H., Fujikawa, J., et al. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.11.013 · Cited by 34 · see citing works
Deciphering the Roles of Thiazolidinediones and PPAR γ in Bladder Cancer
Chiu, M., McBeth, L., Sindhwani, P., & Hinds, T. D. (2017) · PPAR Research · doi:10.1155/2017/4810672 · Cited by 34 · see citing works
Mehtälä, J., Khanfir, H., Bennett, D., Ye, Y., Korhonen, P. A., & Hoti, F. J. (2018) · Diabetology International · doi:10.1007/s13340-018-0360-4 · Cited by 34 · see citing works
Ripamonti, E., Azoulay, L., Abrahamowicz, M., Platt, R. W., & Suissa, S. (2018) · Diabetic Medicine · doi:10.1111/dme.13854 · Cited by 34 · see citing works
Sitagliptin May Reduce Breast Cancer Risk in Women With Type 2 Diabetes
Tseng, C. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.11.002 · Cited by 34 · see citing works
Self-citationPioglitazone use and the risk of bladder cancer
Kuo, H., Tiao, M., Ho, S., & Yang, C. (2013) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2013.09.011 · Cited by 33 · see citing works
Holistic approach to prevention and management of type 2 diabetes mellitus in a family setting
Ofori, S., & Unachukwu, C. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s62320 · Cited by 35 · see citing works
Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes
Tseng, C. (2013) · Annals of Medicine · doi:10.3109/07853890.2013.851865 · Cited by 31 · see citing works
Self-citationKao, C., Sun, L. M., Chen, P., Lin, M.-C., Liang, J., Muo, C.-H., Chang, S.-N., & Sung, F. (2012) · Annals of Oncology · doi:10.1093/annonc/mds472 · Cited by 30 · see citing works
Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes
Tseng, C. (2016) · Oncotarget · doi:10.18632/oncotarget.8399 · Cited by 30 · see citing works
Self-citationProlonged use of human insulin increases breast cancer risk in Taiwanese women with type 2 diabetes
Tseng, C. (2015) · BMC Cancer · doi:10.1186/s12885-015-1876-7 · Cited by 29 · see citing works
Self-citationFaillie, J., Petit, P., Montastruc, J., & Hillaire‐Buys, D. (2013) · Drug Safety · doi:10.1007/s40264-013-0086-y · Cited by 27 · see citing works
Adil, M., Khan, R. A., Ghosh, P., Venkata, S. K., Kandhare, A. D., & Sharma, M. (2017) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2017.08.002 · Cited by 27 · see citing works
Garry, E. M., Buse, J. B., Lund, J. L., Pate, V., & Stürmer, T. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13049 · Cited by 25 · see citing works
Chien, L., Chou, C., Chen, H., Kao, C., Lin, Y., Wu, Y., Chen, J., Chen, L., & Fang, T. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007611 · Cited by 24 · see citing works
Use of Insulin and Mortality from Breast Cancer among Taiwanese Women with Diabetes
Tseng, C.-H. (2015) · Journal of Diabetes Research · doi:10.1155/2015/678756 · Cited by 23 · see citing works
Self-citationDiabetes and breast cancer in T aiwanese women: a detection bias?
Tseng, C. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12323 · Cited by 22 · see citing works
Self-citationDiabetes and cancer relationships (糖尿病与肿瘤的关联性)
Wang, T., Ning, G., & Bloomgarden, Z. T. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12057 · Cited by 21 · see citing works
Chang, H., Hsieh, C.-F., Singh, S., Tang, W., Chiang, Y.-T., & Huang, W.-F. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3770 · Cited by 21 · see citing works
Hsieh, T., Chou, C., Chen, J.-S., Kuo, C., Wang, Y.-C., Lai, Y., Lin, Y., Wang, C., & Fang, T. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.5052 · Cited by 21 · see citing works
Ryder, R. E. J. (2011) · The British Journal of Diabetes · doi:10.1177/1474651411412658 · Cited by 20 · see citing works
Rosiglitazone is not associated with an increased risk of bladder cancer
Tseng, C. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2013.03.013 · Cited by 20 · see citing works
Self-citationKo, S., Han, K., Yun, J. S., Chung, S., & Koh, E. S. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0500 · Cited by 19 · see citing works
Diabetes and risk of bladder cancer among postmenopausal women in the Iowa women’s health study
Prizment, A. E., Anderson, K. E., Yuan, J., & Folsom, A. R. (2013) · Cancer Causes & Control · doi:10.1007/s10552-012-0143-3 · Cited by 19 · see citing works
Tseng, C. (2015) · Annals of Medicine · doi:10.3109/07853890.2015.1091944 · Cited by 18 · see citing works
Self-citationTseng, C. (2013) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2013.04.019 · Cited by 17 · see citing works
Self-citationPioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence
Davidson, M. B. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.04.004 · Cited by 17 · see citing works
Qu, H., Zheng, Y., Wang, Y., Zhang, R., Ruan, X. Z., Yang, G., Liu, Z., & Zheng, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-16074-1 · Cited by 16 · see citing works
Tseng, C.-H. (2022) · International Journal of COPD · doi:10.2147/copd.s345796 · Cited by 16 · see citing works
Self-citationPioglitazone and the risk of bladder cancer
Hillaire‐Buys, D., & Faillie, J. (2012) · BMJ · doi:10.1136/bmj.e3500 · Cited by 16 · see citing works
Kim, D., Ahn, B., Kim, Y. S., Hur, D. Y., Yang, J. W., Park, G. B., Jang, J. E., Lee, E. J., Kwon, M. J., Kim, T. N., et al. (2019) · Journal of Diabetes Research · doi:10.1155/2019/2376512 · Cited by 15 · see citing works
Rosiglitazone may reduce non-melanoma skin cancer risk in Taiwanese
Tseng, C. (2015) · BMC Cancer · doi:10.1186/s12885-015-1057-8 · Cited by 13 · see citing works
Self-citationSitagliptin and heart failure hospitalization in patients with type 2 diabetes
Tseng, C. (2016) · Oncotarget · doi:10.18632/oncotarget.10507 · Cited by 12 · see citing works
Self-citationAssociation Between Pioglitazone and Urothelial Bladder Cancer
Barbalat, Y., Dombrovskiy, V. Y., & Weiss, R. E. (2012) · Urology · doi:10.1016/j.urology.2012.03.032 · Cited by 12 · see citing works
Tseng, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147916 · Cited by 12 · see citing works
Self-citationGarry, E. M., Buse, J. B., Gokhale, M., Lund, J. L., Nielsen, M. E., Pate, V., & Stürmer, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13774 · Cited by 12 · see citing works
Pioglitazone, Bladder Cancer, and the Presumption of Innocence
Papaetis, G. S. (2022) · Current Drug Safety · doi:10.2174/1574886317666220304124756 · Cited by 12 · see citing works
Diabetes and Cancer: Epidemiological, Clinical, and Experimental Perspectives
Tseng, C., Chen, C., & Landolph, J. R. (2012) · Experimental Diabetes Research · doi:10.1155/2012/101802 · Cited by 12 · see citing works
Self-citationBojková, B., Orendáš, P., Kubatka, P., Péč, M., Kassayová, M., Kisková, T., & Kajo, K. (2014) · Pathology - Research and Practice · doi:10.1016/j.prp.2014.06.003 · Cited by 11 · see citing works
Suzuki, H., Sakamoto, M., Hayashi, T., Iuchi, H., Ohashi, K., Isaka, T., Sakamoto, N., Kayama, Y., Tojo, K., Yoshimura, M., et al. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-71 · Cited by 11 · see citing works
Chiang, J., Lin, C., Wang, C.-L., Koo, M., & Kao, Y.-H. (2017) · Medicine · doi:10.1097/md.0000000000006704 · Cited by 11 · see citing works
Pioglitazone does not affect the risk of kidney cancer in patients with type 2 diabetes
Tseng, C. (2014) · Metabolism · doi:10.1016/j.metabol.2014.04.014 · Cited by 10 · see citing works
Self-citationCardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus
Fujihara, K., & Sone, H. (2018) · Annals of Vascular Diseases · doi:10.3400/avd.ra.17-00109 · Cited by 9 · see citing works
Role and application of hysterosalpingography and Fallopian tube recanalization.
Mallarini, G., & Saba, L. (2010) · PubMed · Cited by 9 · see citing works
Focusing on Cardiovascular Disease in Type 2 Diabetes Mellitus: An Introduction to Bromocriptine QR
Bell, D. S. H. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.09.2598 · Cited by 8 · see citing works
- Authors
- Tseng, C.-H.
- Affiliations
- National Taiwan University (TW)
- Corresponding author
- Tseng, Chin-Hsiao
- ORCID
- Tseng, Chin-Hsiao
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-01-16
- Volume
- 35
- Issue
- 2
- Pages
- 278-280
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3263866
- OpenAlex
- W2157761919
- Cited by
- 123
- References
- 14
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 2 · 2019: 5 · 2018: 5 · 2017: 10 · 2016: 12 · 2015: 15 · 2014: 17 · 2013: 24 · 2012: 19
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Health Research Institutes
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- pioglitazone, bladder cancer, type 2 diabetes, drug safety, adverse drug reactions, Asian populations, thiazolidinediones, cancer risk
- MeSH terms
- Pioglitazone, Urinary Bladder Neoplasms, Female, Humans, Hypoglycemic Agents, Male, Asian People, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
